Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACONNASDAQ:BRTXNASDAQ:KDLYNASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACONAclarion$7.32-3.7%$12.64$6.20▼$3,499.51$4.26M1.1356,158 shs16,123 shsBRTXBioRestorative Therapies$1.71-7.1%$1.75$1.03▼$2.55$12.87M77.73542,358 shs163,228 shsKDLYKindly MD$10.35-24.4%$2.09$0.65▼$31.45$62.33MN/A1.76 million shs7.06 million shsMRAIMarpai$1.32-1.5%$0.99$0.40▼$2.35$19.66M4.7419,224 shs6,605 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACONAclarion+7.04%+6.29%-8.76%-93.28%-99.70%BRTXBioRestorative Therapies+2.50%-1.86%+3.07%-19.78%+34.67%KDLYKindly MD+248.35%+405.17%+695.93%+864.08%+1,368,999,900.00%MRAIMarpai+3.08%+27.62%+59.52%+41.05%-40.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACONAclarion1.648 of 5 stars3.32.00.00.02.70.00.6BRTXBioRestorative Therapies3.7919 of 5 stars3.55.00.00.02.43.31.3KDLYKindly MD1.062 of 5 stars0.05.00.00.02.51.70.0MRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACONAclarion 2.50Moderate Buy$11,758.50160,535.25% UpsideBRTXBioRestorative Therapies 3.00Buy$18.00950.05% UpsideKDLYKindly MD 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACONAclarion$45.72K93.17N/AN/A($125.39) per share-0.06BRTXBioRestorative Therapies$401K32.08N/AN/A$2.45 per share0.70KDLYKindly MD$2.72M22.92N/AN/AN/A∞MRAIMarpai$34.87M0.56N/AN/A($1.72) per share-0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACONAclarion-$4.91MN/A0.00N/AN/A-12,845.05%-422.87%-201.15%5/21/2025 (Estimated)BRTXBioRestorative Therapies-$14.41M-$1.16N/AN/AN/A-2,697.08%-98.49%-75.23%5/14/2025 (Estimated)KDLYKindly MDN/A-$0.77N/A∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$2.07N/A∞N/A-85.70%N/A-100.23%5/14/2025 (Estimated)Latest ACON, KDLY, MRAI, and BRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BRTXBioRestorative Therapies-$0.32N/AN/AN/A$0.38 millionN/A5/8/2025Q1 2025KDLYKindly MDN/A-$0.17N/A-$0.17N/AN/A3/28/2025Q4 2024KDLYKindly MDN/A-$0.17N/A-$0.17N/A$0.60 million3/27/2025Q4 2024BRTXBioRestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACONAclarionN/AN/AN/AN/AN/ABRTXBioRestorative TherapiesN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACONAclarionN/A2.802.80BRTXBioRestorative TherapiesN/A2.952.95KDLYKindly MDN/A5.435.42MRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACONAclarion7.52%BRTXBioRestorative Therapies69.38%KDLYKindly MDN/AMRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipACONAclarion0.77%BRTXBioRestorative Therapies25.50%KDLYKindly MD50.50%MRAIMarpai61.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACONAclarion7582,000505,000Not OptionableBRTXBioRestorative Therapies77.51 million5.16 millionNot OptionableKDLYKindly MDN/A6.02 million2.96 millionN/AMRAIMarpai15014.90 million5.61 millionNo DataACON, KDLY, MRAI, and BRTX HeadlinesRecent News About These CompaniesMARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICERMay 13 at 9:01 AM | prnewswire.comMarket Access RICI Agriculture UCITS (MRAI)May 8, 2025 | investing.comMARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comMarpai, Inc. to Present at the Planet MicroCap Showcase Las VegasApril 15, 2025 | prnewswire.comMarpai targets profitability in 2025 with new initiatives and strategic partnershipsMarch 27, 2025 | msn.comMarpai, Inc. (MRAI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comMARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 26, 2025 | prnewswire.comMARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTSMarch 20, 2025 | prnewswire.comMARPAI ACCELERATES HEALTHCARE TRANSFORMATION WITH EMPARA COLLABORATION, LAUNCHING UNIFIED HEALTH ENGAGEMENT PLATFORMMarch 18, 2025 | prnewswire.comHealth In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded SolutionsJanuary 22, 2025 | prnewswire.comMARPAI ANNOUNCES SECOND TRANCHE OF NON-DILUTIVE GROWTH FUNDING WITH UP TO $5 MILLION FROM JGBJanuary 6, 2025 | prnewswire.comMARPAI ANNOUNCES PRICING OF $700,000 PRIVATE PLACEMENTDecember 5, 2024 | prnewswire.comMARPAI ANNOUNCES GENERAL UPDATES FOR Q4November 26, 2024 | prnewswire.comMarpai, Inc. Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comMarpai Inc (MRAI) Q3 2024 Earnings Call Highlights: Strategic Investments and Operational ...November 13, 2024 | finance.yahoo.comMarpai, Inc (MRAI) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comMARPAI REPORTS THIRD QUARTER 2024 FINANCIAL RESULTSNovember 11, 2024 | prnewswire.comMARPAI TO HOST WEBCAST ON NOVEMBER 12, 2024 TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTSNovember 8, 2024 | prnewswire.comMARPAI ANNOUNCES NEW "OFF CYCLE" CLIENT CONTRACTAugust 27, 2024 | prnewswire.comEarnings call: Marpai reports Q2 2024 financial results and turnaround progressAugust 13, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACON, KDLY, MRAI, and BRTX Company DescriptionsAclarion NASDAQ:ACON$7.32 -0.28 (-3.68%) As of 04:00 PM EasternAclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.BioRestorative Therapies NASDAQ:BRTX$1.71 -0.13 (-7.09%) As of 03:59 PM EasternBioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Kindly MD NASDAQ:KDLY$10.35 -3.34 (-24.40%) As of 04:00 PM EasternKindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.Marpai NASDAQ:MRAI$1.32 -0.02 (-1.49%) As of 03:05 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
